

Prioritized List Guideline Note



Extracted from the February 1, 2021 Prioritized List

GUIDELINE NOTE 198, HIDRADENITIS SUPPURATIVA

Lines 419,514

Hidradenitis suppurativa is included on Line 419 only for moderate to severe disease (e.g. Hurley Stage II or Hurley Stage III); otherwise this condition is included on Line 514.

Initial treatment with adalimumab is limited to adults whose disease has not responded to at least a 90-day trial of conventional therapy (e.g., oral antibiotics), unless such a trial is not tolerated or contraindicated. Treatment with adalimumab after 12 weeks is only included on Line 419 for patients with a clear evidence of response, defined as:

- A) a reduction of 25% or more in the total abscess and inflammatory nodule count, AND
- B) no increase in abscesses and draining fistulas.

<https://www.oregon.gov/oha/HPA/DSI-HERC/PrioritizedList/2-1-2021%20Prioritized%20List%20of%20Health%20Services.pdf>